As discussed by Dr Robert Dempster in our recent Prostate cancer seminar, a PSA level alone has limitations as a screening tool as it tends to also pick up the less aggressive forms of Prostate cancer.
A new study which has been published in The Lancet has shown that there may be another way to identify patients who are more at risk by combining the PSA level with three other indicators of risk i.e. genetic markers; clinical variables e.g. age, family history, previous prostate biopsies; and prostate biopsy.
This study demonstrated that when all of these factors are combined to create a risk score, it was easier to identify the more serious Gleason 7 type of Prostate cancer, and is potentially more useful in identifying the more aggressive prostate malignancies.